e-Drug3D

2170

IMLUNESTRANT

INN
IMLUNESTRANT

cas 2408840-26-4

CLASS

ANTINEOPLASTIC
ESTROGEN RECEPTOR ANTAGONIST
TREATMENT OF ADULTS WITH ER-POSITIVE, HER2-NEGATIVE, ESR1-MUTATED ADVANCED OR METASTATIC BREAST CANCER

ROUTE (list)

ORAL

ATC code

PK parameters

F 10 PERCENT
Tmax 4 HOUR
VD 8120 LITER
Cl 166 LITER / HOUR
PPB 99 PERCENT
t1/2 30 HOUR

Solubility

INSOLUBLE AT NEUTRAL PH AND SPARINGLY SOLUBLE AT HIGH PH IN WATER

Target

TARGET ESTROGEN RECEPTOR ALPHA

Download SDF file

5H-[1]Benzopyrano[4,3-c]quinolin-2-ol, 5-[4-[2-[3-(fluoromethyl)-1-azetidinyl]ethoxy]phenyl]-8-(trifluoromethyl)-, (5R)-

Formula:
C29H24F4N2O3

Calculated chemical properties:

MW 524.50
NB_atoms 38
XLogP 6.39
PSA 56.955
NB_HD 1
NB_HA 5
fsp3 0.28
Lipinski(0=no;1=yes) 0

FDA
NDA 218881 (label) INN (IMLUNESTRANT TOSYLATE) INLURIYO (ELI LILLY AND CO) APPROVAL= AP YEAR= 2025 NEWMOLECULARENTITY